Please login to the form below

Not currently logged in
Email:
Password:

vosoritide

This page shows the latest vosoritide news and features for those working in and with pharma, biotech and healthcare.

BioMarin ticks over in Q2 ahead of gene therapy filing

BioMarin ticks over in Q2 ahead of gene therapy filing

valrox and vosoritide, its late stage candidate for achondroplasia, (the most common form of dwarfism) which they say have potential to drive significant growth in the next few years.

Latest news

  • Pfizer buys dwarfism drug company Therachon for $810m Pfizer buys dwarfism drug company Therachon for $810m

    Therachon isn’t the only company developing a drug for achondroplasia however, and Pfizer could find itself playing catch-up with BioMarin, which has a drug called vosoritide in phase 3

  • BioMarin eyes 2019 FDA filing for haemophilia A gene therapy BioMarin eyes 2019 FDA filing for haemophilia A gene therapy

    During the update, BioMarin also laid out its expectations for vosoritide, a drug for short stature in children with achondroplasia in a phase 3 trial due to read out before the ... growth. Vosoritide – an analogue of C-type natriuretic peptide (CNP)

  • BioMarin drug boosts growth in children with dwarfism BioMarin drug boosts growth in children with dwarfism

    While the gain in overall height was significant in the 26-patient trial vosoritide seemed to have no impact on body ratio. ... The hope is that vosoritide will continue to work over several years, providing a much greater increase in adult stature than

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics